Fig. 2

Time course of events in the SATS according to concomitant medications. Mean age at AD onset, illness duration, time from diagnosis (start of cholinesterase inhibitor treatment) to NHP, and survival time in NHs. a Antihypertensive/cardiac therapy. The participants without antihypertensive/cardiac therapy were younger at the onset of AD symptoms (P < 0.001), had a longer illness duration (P = 0.004), and were younger at the time of diagnosis (P = 0.003) and at NHP (P = 0.002) compared with the individuals who received these medications. The survival time in NHs was, on average, 1 year longer for patients with no antihypertensive/cardiac therapy (P = 0.007). No significant difference was found regarding time between diagnosis and NHP, and age at death. b Anxiolytics/sedatives/hypnotics. The participants without these medications were younger at the onset of AD (P = 0.008), at the time of diagnosis (P = 0.011), and younger at NHP (P = 0.018) compared with the individuals who received anxiolytics/sedatives/hypnotics. The survival time in NHs was a mean of 1 year shorter for users of these medications (P = 0.032). No significant difference was observed regarding illness duration, time between diagnosis and NHP, and age at death. AD, Alzheimer’s disease; NH, nursing home; NHP, nursing home placement; SATS, Swedish Alzheimer Treatment Study